THC, an intoxicating and illegal substance, is responsible for causing marijuana users to get “high.” Unlike THC, CBD is non-psychoactive because it does not act on the same pathways as THC. Thus, it is impossible to get “high” by smoking or ingesting CBD or CBD oil extracted from industrial hemp plants, as they only have minuscule traces of THC (<0.3%).
FAAH breaks down and removes natural endocannabinoids. CBD stops this breakdown and in turn increases the natural endocannabinoids available to the body. Because endo- cannabinoids have a balancing and healing effect on the body’s numerous systems and functions, CBD’s ability to increase the amount of endocannabinoids available to the body may create a bevy of therapeutic benefits5
In the United States, non-FDA approved CBD products are classified as Schedule I drugs under the Controlled Substances Act. This means that production, distribution, and possession of non-FDA approved CBD products is illegal under federal law. In addition, in 2016 the Drug Enforcement Administration added "marijuana extracts" to the list of Schedule I drugs, which it defined as "an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant." Previously, CBD had simply been considered "marijuana", which is a Schedule I drug.
Both CBD oil and CBD cream products have their own unique and significant uses throughout the medical world. They are both highly capable of healing and diminishing pain plus daily discomforts. This all-natural alternative to conventional medications is reasonably affordable and does not produce any of the psychoactive or “high” effects that traditional marijuana flower can, meaning that CBD could be consumed any day of the week at any time of day, leading to its extreme versatility and convenience.
In addition to positively affecting the endocannabinoid system, CBD has been the focus of more than 23,000 published studies about cannabinoids in relation to various medical indications including anxiety, epilepsy, inflammation, cancer and chronic pain to name few. For a more comprehensive look at these and other studies, visit our medical research and education page.
Despite this, CBD is something nobody knows much about, and certainly nobody is monitoring it properly. CBD is widely marketed as a supplement, despite the Food and Drug Administration saying it does not qualify as such (this is because it is an active ingredient in drugs which are either approved or under investigation to be approved). CBD goes largely unregulated by the agency; on the FDA’s FAQ page, a vague answer maintains there are “many factors in deciding whether or not to initiate an enforcement action.” The Department of Agriculture handles research grants and pilot programs for hemp, but that’s where its involvement ends.